40.19
Harrow Inc stock is traded at $40.19, with a volume of 711.86K.
It is up +4.26% in the last 24 hours and down -14.72% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
See More
Previous Close:
$38.60
Open:
$39.31
24h Volume:
711.86K
Relative Volume:
1.18
Market Cap:
$1.49B
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-41.87
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
-24.68%
1M Performance:
-14.72%
6M Performance:
+11.19%
1Y Performance:
+54.16%
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
HROW
Harrow Inc
|
40.17 | 1.43B | 154.15M | -33.58M | -20.74M | -0.96 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.20 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.22 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.52 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.43 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
492.42 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Harrow (HROW) Q4 2025 Earnings Call Transcript - AOL.com
HROW: 2025 revenue grew 36% with strong momentum and 2026 guidance set at $350M–$365M - TradingView
HROW: Strong 2025 growth and expanded sales force set the stage for accelerated 2026 revenue - TradingView
Harrow Stock Falls 21% After FDA Clears IND Application For Phase 3 Trial Of TRIESENCE - Nasdaq
MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
HROW Gains FDA Approval for Phase 3 Trial of Triesence - GuruFocus
Harrow, Inc. (HROW) Stock Analysis: A 31.79% Upside in the Healthcare Sector Beckons Investors - DirectorsTalk Interviews
HROW: 2025 delivered robust revenue and EBITDA growth, with 2026 set for further expansion - TradingView
Eye drug TRIESENCE moves into Phase 3 test to ease cataract surgery recovery - Stock Titan
Harrow’s PharmaPack Aims To Reshape Post Cataract Care And Cash Pay Use - simplywall.st
Harrow Q4 Net Income Slips Despite 33% Revenue Growth; Issues FY26 Guidance; Stock Down - Nasdaq
Harrow Reports Substantial Q4 and Full-Year 2025 Revenue Growth - VisionMonday.com
Harrow Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Harrow (HROW) Misses Q4 Earnings Estimates - Nasdaq
Harrow Health (HROW) Q4 Earnings Miss Despite Revenue Beat - GuruFocus
Harrow (HROW) Sets Ambitious Financial Targets for FY26 - GuruFocus
Harrow Reports Q4 Earnings - National Today
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance - Bitget
Harrow Health Posts Record 2025 Results, Sets 2026 Outlook - TipRanks
Harrow: Q4 Earnings Snapshot - Citizen Tribune
Harrow Health Stock Slides After 2026 Outlook Shock - TipRanks
Harrow Inc. (HROW) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Harrow : Q4-2025 Letter to Stockholders - marketscreener.com
Harrow Earnings Review: Q4 Summary - Benzinga
HROW: 2025 revenue surged 36% to $272.3M, net loss narrowed, and branded sales led growth - TradingView
Harrow 10-K: $272.3M Revenue, $(0.14) EPS on improved net loss - TradingView
[10-K] HARROW, INC. Files Annual Report | HROW SEC FilingForm 10-K - Stock Titan
Earnings Flash (HROW) Harrow Posts Q4 EPS $0.17, vs. FactSet Est of $0.37 - marketscreener.com
Harrow (NASDAQ: HROW) lifts 2025 revenue 36% and sets 2026 outlook - Stock Titan
Why Is Eye-Disease-Focused Harrow Stock Falling Today? - Bitget
Earnings Flash (HROW) Harrow, Inc. Reports Q4 Revenue $89.1M, vs. FactSet Est of $90.0M - marketscreener.com
All eyes on Harrow Health earnings amid VEVYE coverage win - Investing.com
Harrow, Inc. $HROW Shares Sold by Royce & Associates LP - MarketBeat
88,855 Shares in Harrow, Inc. $HROW Bought by Lumbard & Kellner LLC - MarketBeat
Harrow: Q4 Financial Overview - Bitget
Harrow, Inc. (HROW): A Bull Case Theory - Yahoo Finance
HROW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Harrow Health (HROW) Set to Announce Q4 Earnings - GuruFocus
A Preview Of Harrow's Earnings - Benzinga
Harrow’s PharmaPack Aims To Reshape Cataract Surgery Prescribing And Access - simplywall.st
Harrow Bets On AI And PharmaPack To Reshape Ophthalmic Distribution - Yahoo Finance
Is It Too Late To Look At Harrow Health (HROW) After Its 1-Year 90% Surge? - simplywall.st
Harrow, Inc. (HROW) Investor Outlook: A Potential 37% Upside in the Eyecare Pharmaceuticals Sector - DirectorsTalk Interviews
Harrow (HROW) Is Up 8.1% After Launching PharmaPack Cash-Pay Ophthalmic Kits For Cataract Surgery - simplywall.st
Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
FOMO Trade: Does Harrow Inc have strong EBITDA marginsMarket Volume Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Will Harrow Inc. stock attract more institutional investorsMarket Growth Report & Expert Verified Movement Alerts - mfd.ru
Harrow to Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 - The Manila Times
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits - markets.businessinsider.com
Harrow, Inc. Announces Cash-Pay Direct-To-Prescriber Pharmapack?? Kits - marketscreener.com
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harrow Inc Stock (HROW) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Jan 06 '26 |
Sale |
53.35 |
20,000 |
1,066,914 |
70,000 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
Dec 12 '25 |
Option Exercise |
3.95 |
60,000 |
237,000 |
837,844 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Dec 12 '25 |
Option Exercise |
3.95 |
180,000 |
711,000 |
3,066,124 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Jul 21 '25 |
Option Exercise |
7.87 |
600,000 |
4,722,000 |
3,199,462 |
| Opaleye Management Inc. | 10% Owner |
Jun 10 '25 |
Sale |
30.80 |
15,000 |
462,033 |
90,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 09 '25 |
Sale |
30.37 |
15,204 |
461,794 |
105,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 03 '25 |
Sale |
30.04 |
3,000 |
90,116 |
122,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 04 '25 |
Sale |
30.02 |
1,796 |
53,907 |
120,204 |
| Opaleye Management Inc. | 10% Owner |
May 12 '25 |
Sale |
25.90 |
10,000 |
258,959 |
130,000 |
| Opaleye Management Inc. | 10% Owner |
May 13 '25 |
Sale |
26.59 |
5,000 |
132,945 |
125,000 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):